Tuberculosis (TB) continues to be a major global health problem with 9 million new cases per year resulting in 1.7 million deaths [1], due in large part to the HIV epidemic and emergence of multi- and extensively drug resistant TB strains (MDR- and XDR-TB) that have confounded TB control. There will be no lasting reduction of TB morbidity and mortality without rapid and cost-effective TB diagnostics, efficacious vaccines, and shortened, well-tolerated chemotherapy, which can only be developed on the foundation of understanding the biology of the tubercle bacilli and subsequent host-pathogen interactions. The goal of this proposal is to accelerate TB research through the completion and distribution of these valuable precise null deletion M. tuberculosis gene knockout resources to the international TB research community. We will partner with BEI for distribution of reagents.

Public Health Relevance

Tuberculosis (TB) continues to be a major global health problem with 9 million new cases per year resulting in 1.7 million deaths. There will be no lasting reduction of TB morbidity and mortality without rapid and cost-effective therapuetics. The goal of this proposal is to accelerate TB research through the completion and distribution of these valuable precise null deletion M. tuberculosis gene knockout resources to the international TB research community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Resource-Related Research Projects (R24)
Project #
5R24AI134650-02
Application #
9565493
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Boyce, Jim P
Project Start
2017-09-14
Project End
2022-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine, Inc
Department
Type
DUNS #
079783367
City
Bronx
State
NY
Country
United States
Zip Code
10461